TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Return
18.15%
This Quarter Return
+1.3%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.45B
AUM Growth
-$11.8M
(-0.48%)
Cap. Flow
-$7.06M
Cap. Flow
% of AUM
-0.29%
Top 10 Holdings %
Top 10 Hldgs %
40.31%
Holding
207
New
13
Increased
45
Reduced
58
Closed
10
Top Buys
| 1 |
Vertex Pharmaceuticals
VRTX
|
$8.44M |
| 2 |
Intuitive Surgical
ISRG
|
$8.07M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$7.96M |
| 4 |
Boston Scientific
BSX
|
$6.82M |
| 5 |
Gilead Sciences
GILD
|
$5.86M |
Top Sells
| 1 |
Biogen
BIIB
|
$21M |
| 2 |
Illumina
ILMN
|
$14.4M |
| 3 |
Elevance Health
ELV
|
$10.7M |
| 4 |
AGN
Allergan plc
AGN
|
$8.2M |
| 5 |
Welltower
WELL
|
$6.93M |
Sector Composition
| 1 | Healthcare | 95.11% |
| 2 | Real Estate | 2.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN
26
DELISTED
Allergan plc
AGN
| $24.2M | 0.99% |
144,281
-48,982
| -25% | -$8.2M |
|
27
Danaher
DHR
$143B
| $22.7M | 0.93% |
179,274
| – | – |
|
28
Sarepta Therapeutics
SRPT
$1.93B
| $22.5M | 0.92% |
147,847
| – | – |
|
29
Stryker
SYK
$151B
| $21.2M | 0.86% |
102,950
-20,100
| -16% | -$4.13M |
|
30
BioMarin Pharmaceuticals
BMRN
$10.9B
| $21.1M | 0.86% |
245,763
+23,677
| +11% | +$2.03M |
|
|
SGEN
31
DELISTED
Seagen Inc. Common Stock
SGEN
| $20.1M | 0.82% |
289,925
| – | – |
|
32
Cigna
CI
$81.2B
| $18.4M | 0.75% |
116,756
| – | – |
|
33
Viatris
VTRS
$12B
| $18M | 0.73% |
943,152
| – | – |
|
34
Neurocrine Biosciences
NBIX
$13.9B
| $17.5M | 0.71% |
207,078
-14,600
| -7% | -$1.23M |
|
35
Idexx Laboratories
IDXX
$51.2B
| $17M | 0.69% |
61,754
-1,900
| -3% | -$523K |
|
|
SAGE
36
DELISTED
Sage Therapeutics
SAGE
| $15.4M | 0.63% |
84,145
+4,289
| +5% | +$785K |
|
|
PRAH
37
DELISTED
PRA Health Sciences, Inc.
PRAH
| $15.2M | 0.62% |
153,003
+9,466
| +7% | +$939K |
|
|
ARRY
38
DELISTED
Array Biopharma Inc
ARRY
| $15M | 0.61% |
323,883
-40,283
| -11% | -$1.87M |
|
39
Becton Dickinson
BDX
$54.8B
| $14.7M | 0.6% |
59,899
-3,365
| -5% | -$827K |
|
40
Exelixis
EXEL
$10.1B
| $14.5M | 0.59% |
678,467
| – | – |
|
41
Baxter International
BAX
$12.1B
| $14.5M | 0.59% |
176,698
+39,030
| +28% | +$3.2M |
|
42
AstraZeneca
AZN
$254B
| $13.8M | 0.56% |
334,998
-26,000
| -7% | -$1.07M |
|
|
BLUE
43
DELISTED
bluebird bio
BLUE
| $13M | 0.53% |
7,868
+841
| +12% | +$1.39M |
|
44
Edwards Lifesciences
EW
$47.5B
| $12.9M | 0.53% |
209,307
+38,913
| +23% | +$2.4M |
|
45
McKesson
MCK
$86B
| $12.9M | 0.52% |
95,691
+24,971
| +35% | +$3.36M |
|
46
Humana
HUM
$37.5B
| $12.8M | 0.52% |
48,122
+12,440
| +35% | +$3.3M |
|
|
47
Welltower
WELL
$112B
| $12.4M | 0.51% |
152,322
-85,000
| -36% | -$6.93M |
|
48
Novo Nordisk
NVO
$249B
| $12.3M | 0.5% |
482,000
-21,200
| -4% | -$541K |
|
49
HCA Healthcare
HCA
$96.3B
| $12.1M | 0.49% |
89,569
| – | – |
|
50
Cencora
COR
$56.7B
| $12M | 0.49% |
140,273
+61,047
| +77% | +$5.21M |
|